BAGNEUX, France, Aug. 26, 2014 (GLOBE NEWSWIRE) -- DBV Technologies, (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, today announced that the Company's management will be hosting investor meetings during the Goldman Sachs European Biotech Symposium to be held in London on Friday, September 5, 2014.
About DBV Technologies
DBV Technologies is developing Viaskin®, an innovative new approach to the treatment of allergies - a major public health issue that is constantly increasing in prevalence. DBV Technologies, incorporated in France in 2002, has developed a proprietary, worldwide-patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus considerably lowers the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies has designed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration and is currently being studied in Phase II program.
DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contacts
| David Schilansky |
Chief Financial Officer
Tel. : +33(0)1 55 42 78 75
VP Finance, US Investor Relations & Strategy
Tel. : +1 917-346-3447
Director, Corporate Communication & Business Development
Tel. : +33(0)1 55 42 78 72
DBV IR and Media Contacts
U.S. Investor Relations
The Trout Group
Tel. : +1 646-378-2926
Rooney & Associates
Tel. : +1-212-223-4017
DBV to Attend the Goldman Sachs European Biotech Symposium http://hugin.info/156437/R/1850952/646400.pdf